by Chilmark Team | November 01, 2018
[Guest Post] Health system and health plan leaders across the country are asking the same question: how will our organizations survive and thrive in a value-based world? As the shift to lower-cost settings accelerates and the population becomes older and sicker, organizations are seeking new ways to manage costs, generate income and control quality.
by John Moore | August 14, 2018
Last week, CMS released its proposed rule (beware – in good government fashion it’s a whooping 607 pages) for the […]
by Paul Nardone | July 26, 2018
Key Takeaways: Healthcare stakeholders recognize a social determinant of health when they see it, but organizations differ on which measures […]
by Brian Murphy | February 16, 2018
Key Takeaway PHM products are maturing in spite of uncertainty about payment system. The Chilmark Research 2018 Population Health Management […]
by Janice Young | September 07, 2017
This post originally appeared on the blog for our upcoming Convergence 2017 conference.
In a recent blog, I observed an emerging convergence trend – that of the shared information platform. As providers and payers converge, they need to collaborate efficiently and accurately, particularly as they align on reimbursement strategies and population health management (PHM) programs.
by Jennifer Rogers | July 25, 2017
Prior Authorization is often viewed as the poster child for throwing the Quadruple Aim off balance with its pursuit of […]
by John Moore | February 15, 2017
The final countdown has begun. In a few short days I and the rest of the Chilmark Research team will make our annual pilgrimage to the big health IT confab, HIMSS17, to rub shoulders with some 45,000 of our closest friends.
by Jody Ranck | August 20, 2015
The move to Value Based Care (VBC) is changing the relationships that pharma has historically had with both payers and providers. The growing chronic disease burden, rise of digital health and commoditization of many drug-disease areas is forcing a rethinking of the underlying pharmaceutical (pharma) business model.